TISLELIZUMAB IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER, SINGLE-ARM, EXPLORATORY PHASE I I CLINICAL STUDY-MedSci.cn

TISLELIZUMAB IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER, SINGLE-ARM, EXPLORATORY PHASE I I CLINICAL STUDY

Laoguo, SX; Huang, HS; Zeng, J; Jiang, YF; Liu, CZ; Mo, N; Zhu, GZ; Ma, FC; Peng, T; Yang, LH; Zeng, ZM; Ma, J

HEPATOLOGY, 2023; 78 (): S1904

科室
- - 订阅+
  - 更多科室
工具
服务